β-Glucuronidase-Cleavable Prodrugs of O6-Benzylguanine and O6-Benzyl-2‘-deoxyguanosine
- 13 December 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 48 (1) , 256-261
- https://doi.org/10.1021/jm0493865
Abstract
Glucuronic acid linked prodrugs of O6-benzylguanine and O6-benzyl-2‘-deoxyguanosine were synthesized. The prodrugs were found to be quite stable at physiological pH and were more than 200-fold less active as inactivators of O6-alkylguanine-DNA alkyltransferase (alkyltransferase) than either O6-benzylguanine or O6-benzyl-2‘-deoxyguanosine. β-Glucuronidase from both Escherichia coli and bovine liver cleaved the prodrugs efficiently to release O6-benzylguanine and O6-benzyl-2‘-deoxyguanosine, respectively. In combination with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), the prodrugs were not effective adjuvants for HT29 cell killing. However, as expected, incubation of these prodrugs with β-glucuronidase in the culture medium led to much more efficient cell killing by BCNU as a result of the liberation of the more potent inactivators, O6-benzylguanine and O6-benzyl-2‘-deoxyguanosine. These prodrugs may be useful for prodrug monotherapy of necrotic tumors that liberate β-glucuronidase or for antibody-directed enzyme prodrug therapy with antibodies that can deliver β-glucuronidase to target tumor cells.Keywords
This publication has 14 references indexed in Scilit:
- Phase II Trial of Carmustine Plus O6-Benzylguanine for Patients With Nitrosourea-Resistant Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 2002
- Prodrugs of Anthracyclines for Use in Antibody-Directed Enzyme Prodrug TherapyJournal of Medicinal Chemistry, 1998
- Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT) : A phenol nitrogen mustard carbamateBioorganic & Medicinal Chemistry Letters, 1997
- Intraarterial O 6 -benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosoureaCancer Chemotherapy and Pharmacology, 1997
- Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-BIS(2-chloroethyl)-1-nitrosourea(BCNU)Biochemical Pharmacology, 1993
- Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferaseJournal of Medicinal Chemistry, 1992
- A cytotoxic agent can be generated selectively at cancer sitesBritish Journal of Cancer, 1988
- Antibody directed enzymes revive anti-cancer prodrugs conceptBritish Journal of Cancer, 1987
- Prodrugs and site-specific drug deliveryJournal of Medicinal Chemistry, 1980
- Rationale for Design of Biologically Reversible Drug Derivatives: ProdrugsJournal of Pharmaceutical Sciences, 1975